CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.

Blood Cancer J · 2026 · PMC13186987 · PMID 41942467

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

Notably, frontline treatment with CPX-351 showed a trend toward inferior OS compared with Ven-HMA (HR 1.3 95% CI 0.9–1.8, p = 0.09, Supplemental Fig. 4).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.